Register NOW for the FREE IMF Virtual Myeloma Community Workshop

Welcome and Introductions
Robin Tuohy, 26-year Myeloma Care Partner
IMF, Vice President, Patient Support 

What is Relapse and How do we Deal with it?
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
(TGen, City of Hope—Phoenix, AZ)

What are the Key Treatments we have for Relapsed Myeloma?
Betsy O’Donnell, MD
Dana-Farber Cancer Institute—Boston, MA)

CAR-T Cell Therapy: What it is and How we deliver it 
Luciano Costa, MD
University of Alabama Medicine, The Kirklin Clinic, Birmingham, AL

Myeloma: Putting the Pieces of the Puzzle Together
Patricia Mangan, RN, MSN, APRN-BC
IMF Nurse Leadership Board Member
(University of Pennsylvania, Abramson Cancer Center — Philadelphia, PA )

Faculty Roundtable: The Importance of Clinical Trials

Q&A with Panel

Closing Remarks

Additional Resources:

Download the IMF's Multiple Myeloma Informational Booklets:

Download IMF publications

What Is a Clinical Trial?

*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:

• CANOVA Clinical Trial Fact Sheet
  clinicaltrials.gov Identifier: NCT03539744
• Phase II Relapsed or Refractory Venetoclax Trial 
  clinicaltrials.gov Identifier: NCT02899052
• Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib 
  clinicaltrials.gov Identifier: NCT03314181